Third Harmonic Bio Announces Stockholder Approval of Plan of Liquidation and Dissolution, Updated THB335 Phase 1 Clinical Data, and Initiation of Sale of THB335

Core Viewpoint - Stockholders of Third Harmonic Bio, Inc. have overwhelmingly approved the Plan of Liquidation and Dissolution, with an initial distribution expected between $5.30 and $5.35 per share in Q3 2025 [2][3][4] Group 1: Plan of Liquidation and Dissolution - The Plan of Dissolution received 99.9% approval from voting shareholders and 83.7% of total outstanding common shares [3] - The company anticipates finalizing the Plan of Dissolution and making initial distributions to stockholders in Q3 2025 [3][4] - Total distributions are estimated to be between $5.30 and $5.44 per share, excluding potential cash from asset sales [4] Group 2: THB335 Clinical Trial and Sale Process - THB335 demonstrated an 85% reduction in serum tryptase levels in a Phase 1 clinical trial cohort with a 100mg dose [6] - The company has completed all necessary clinical, toxicology, and manufacturing activities to support a Phase 2 trial for THB335 and plans to submit a regulatory filing to the FDA [8] - A sale process for THB335 and related intellectual property has been initiated, with interested parties encouraged to contact the company [9]